Pembrolizumab vs Placebo as Postnephrectomy Adjuvant Therapy for Patients With Clear Cell Renal Cell Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Lancet Oncol 2022 Sep 01;23(9)1133-1144, T Powles, P Tomczak, SH Park, B Venugopal, T Ferguson, SN Symeonides, J Hajek, H Gurney, YH Chang, JL Lee, N Sarwar, A Thiery-Vuillemin, M Gross-Goupil, M Mahave, NB Haas, P Sawrycki, JE Burgents, L Xu, K Imai, DI Quinn, TK ChoueiriFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.